Benzinga · Feb 2, 2026
Prokidney Updates Phase 3 REGEN-006 Trial Enrollment Of ~470 Subjects
SEC Filing.
PR
NASDAQ · PROK
ProKidney Corp.
Healthcare · Biotechnology
$1.61
Up+$0.01 (+0.62%)
Updated Sep 29, 2026, 9:39 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 623.32M
- P/E ratio
- -4
- Dividend yield
- 0.00%
- 52-week range
- $1.30 – $3.48
- Volume
- 1.81M
- Avg. volume
- 1.98M
Price performance · PROK
PROK price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
PROK closed at $1.61 after 20 trading sessions, down 14.81% for the selected period.
- Last close
- $1.61
- Period change
- -14.81%
- Period low
- $1.60
- Period high
- $2.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $1.58 | $1.64 | $1.54 | $1.61 | 1.81M |
| Sep 25, 2026 | $1.67 | $1.69 | $1.565 | $1.60 | 2.17M |
| Sep 24, 2026 | $1.65 | $1.6891 | $1.60 | $1.68 | 1.73M |
| Sep 23, 2026 | $1.81 | $1.84 | $1.65 | $1.65 | 1.44M |
| Sep 22, 2026 | $1.78 | $1.86 | $1.772 | $1.83 | 588.52K |
| Sep 21, 2026 | $1.90 | $1.9094 | $1.715 | $1.775 | 1.77M |
| Sep 18, 2026 | $1.79 | $1.98 | $1.79 | $1.91 | 9.45M |
| Sep 17, 2026 | $1.87 | $1.905 | $1.80 | $1.80 | 1.05M |
| Sep 16, 2026 | $1.79 | $1.86 | $1.76 | $1.85 | 1.81M |
| Sep 15, 2026 | $1.81 | $1.8281 | $1.72 | $1.74 | 1.2M |
| Sep 14, 2026 | $1.80 | $1.845 | $1.79 | $1.81 | 952.6K |
| Sep 11, 2026 | $1.88 | $1.925 | $1.80 | $1.80 | 1.07M |
| Sep 10, 2026 | $1.82 | $1.86 | $1.75 | $1.84 | 2.49M |
| Sep 9, 2026 | $1.98 | $1.985 | $1.83 | $1.85 | 1.41M |
| Sep 8, 2026 | $2.05 | $2.08 | $1.97 | $1.99 | 929.61K |
| Sep 4, 2026 | $1.90 | $2.09 | $1.89 | $2.01 | 1.23M |
| Sep 3, 2026 | $1.92 | $1.995 | $1.895 | $1.92 | 751.47K |
| Sep 2, 2026 | $1.86 | $1.95 | $1.845 | $1.91 | 641.22K |
| Sep 1, 2026 | $1.86 | $1.90 | $1.825 | $1.85 | 695.73K |
| Aug 31, 2026 | $1.83 | $1.915 | $1.7807 | $1.89 | 1.26M |
Latest PROK news
The latest Smart Investors Daily articles mentioning PROK.
Stock researchCompany · Overview
PROK research
Overview
Company profile and research snapshot.
Company profile
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | UBS | Buy | — |
| Jul 14, 2025 | Guggenheim | Buy | — |
| Jul 9, 2025 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 31, 2026
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
ProKidney Corp. targets diabetic CKD with Rilparencel and expects Q2 2027 eGFR slope data for accelerated approval. Find out why PROK stock is a buy.
SeekingAlpha · Jan 14, 2026
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney Corp. (PROK) 44th Annual J.P.
SeekingAlpha · Jan 14, 2026
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-14. The following slide deck was published by ProKidney Corp.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
